At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 22, 2018·Updated Jun 15, 2025
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Relatlimab for Microsatellite Stable (MSS) Colorectal Adenocarcinomas and Colorectal Adenocarcinoma. Completed, enrolled 59 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartFeb 2019
Primary CompletionFeb 2024
Study CompletionSep 2024
TodayJul 2026
First PostedAug 22, 2018
Enrollment StartFeb 12, 2019
Primary CompletionFeb 23, 2024
Study CompletionSep 18, 2024
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.9 years ago
Interventions
Nivolumabdrug
Nivolumab was administered IV on day 1 of each 28 day cycle.
Relatlimabdrug
Relatlimab was administered IV on day 1 of each 28 day cycle.